Multidisciplinary Design and Characterization of Novel cis- and trans-Ferrocene–Platinum Anticancer Candidates
Year: 2026
Type: preprint
Abstract: The limitations of the classical platinum-based drugs (i.e. cisplatin, carboplatin, oxaliplatin), such as adverse side-effects and drug resistance, highlight the need to develop alternative metal-based anticancer compounds. In this context, molecules that bear two pharmacologically active motifs represent a versatile strategy, as they may enhance therapeutic efficacy through synergistic effects, being the synthesis of this type of drugs a promising research field. In the present study, we report the preparation and characterization of new heterometallic Pt(II) complexes bearing the p-ferrocenylaniline ligand ( L ) using K 2 [PtCl 4 ] and cis-[PtCl 2 (DMSO) 2 ] as precursors. The reactions lead to mixtures of the cis and trans isomers of the products [PtCl 2 L 2 ] and [PtCl 2 (DMSO) L ], isolating only one isomer in both cases: the cis isomer for the disubstituted complex and the trans for the monosubstituted product. Different synthetic routes are explored to assess the influence of solvent polarity, reaction time and temperature on the formation of the cis/trans isomers of [PtCl 2 (DMSO) L ]. The results are supported by the thermodynamic stability obtained by DFT calculations, considering none or four explicit solvent molecules of water, acetone or dichloromethane, observing an increase in the Boltzmann distribution of the cis isomer with the solvent polarity. A more in depth study of the non-covalent interactions between the isomers and the solvent molecules is performed. Alternatively, the study of the reaction mechanism to afford the isomers of [PtCl 2 (DMSO) L ] suggests an isomerization process from the cis to the trans isomer through a dissociative pathway, which is enhanced due to the presence of the aromatic moiety in the ferrocene ligand. These findings offer new insight into controlled isomer formation in ferrocene-containing Pt(II) complexes and may contribute to the rational design of heterometallic anticancer agents.
Source: ChemRxiv
Institution: Universidad Autónoma de Madrid
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: G7285452551, G7802240145
OpenAlex ID: W7235101950
